Fibroscan / VCTE: Normal vs. Functional Optimal Ranges

What Is Fibroscan / VCTE and Why Does It Matter?

Fibroscan is the brand name for a device that performs vibration-controlled transient elastography (VCTE), a noninvasive ultrasound-based technique that quantifies liver stiffness and hepatic fat content in a single exam. The test takes under 10 minutes. No needles. No sedation. The probe sits against the skin overlying the right lobe of the liver and transmits a low-frequency shear wave; the speed at which that wave propagates through hepatic tissue correlates directly with the degree of fibrosis [1].

Two measurements come back from every scan. The liver stiffness measurement (LSM), reported in kilopascals (kPa), estimates fibrosis stage. The controlled attenuation parameter (CAP), reported in decibels per meter (dB/m), estimates hepatic steatosis grade. Both values are operator-independent and reproducible, which is why the American Association for the Study of Liver Diseases (AASLD) now positions VCTE as a first-line noninvasive test for metabolic dysfunction-associated steatotic liver disease (MASLD) staging [2].

The distinction between a "normal" result and a "functionally optimal" result matters because standard reference ranges were built to detect disease, not to define metabolic health. A stiffness reading of 6.8 kPa is technically normal. It also sits just below the threshold for significant fibrosis, meaning subclinical inflammation or early-stage fat infiltration may already be present.

Standard Reference Ranges for Liver Stiffness (LSM)

The widely adopted fibrosis staging cutoffs for MASLD derive from a 2010 meta-analysis of 40 studies encompassing over 7,000 patients, later refined by the Baveno VII consensus in 2022 [3]. These cutoffs stratify liver stiffness into fibrosis stages (F0 through F4).

For MASLD specifically, the AASLD practice guidance published in 2023 endorses the following thresholds: LSM below 8.0 kPa rules out advanced fibrosis (F3 or higher) with a negative predictive value exceeding 90%, while LSM at or above 12.0 kPa rules in advanced fibrosis with a positive predictive value of roughly 80% [2]. Values between 8.0 and 12.0 kPa fall into a "gray zone" where secondary testing (such as the Enhanced Liver Fibrosis [ELF] panel or magnetic resonance elastography) is recommended.

The Baveno VII consensus statement specifies that patients with compensated advanced chronic liver disease (cACLD) can be identified when LSM reaches or exceeds 10 kPa on two separate occasions, and that a reading below 10 kPa combined with normal platelet count (>150 × 10⁹/L) effectively excludes clinically significant portal hypertension [3]. In population-based screening studies, mean LSM in healthy adults without liver disease ranges from 4.5 to 5.5 kPa [4].

A practical staging framework used by hepatologists:

| Fibrosis Stage | LSM Cutoff (MASLD) | Interpretation | |---|---|---| | F0-F1 | <7.0 kPa | No significant fibrosis | | F2 | 7.0 to 9.4 kPa | Moderate fibrosis | | F3 | 9.5 to 13.5 kPa | Advanced fibrosis | | F4 | ≥13.6 kPa | Cirrhosis |

These cutoffs vary slightly by liver disease etiology. For hepatitis C, the F4 threshold drops to approximately 12.5 kPa; for hepatitis B, it rises to 14.0 kPa [1]. Always interpret your LSM in the context of the clinical indication your provider ordered it for.

Standard Reference Ranges for CAP Score

The CAP score estimates hepatic steatosis on a scale from 100 to 400 dB/m. A 2019 individual-patient meta-analysis of 19 studies (N=3,830) established the following steatosis grading cutoffs using liver biopsy as the reference standard [5]:

• S0 (no steatosis): CAP below 248 dB/m
• S1 (mild, 5-33% fat): 248 to 267 dB/m
• S2 (moderate, 34-66% fat): 268 to 279 dB/m
• S3 (severe, >66% fat): 280 dB/m or above

These thresholds have moderate sensitivity (between 69% and 80%) and specificity (between 71% and 82%), which means that a single CAP reading close to a cutoff should be interpreted cautiously [5]. Repeat testing after a 4-hour fast improves reliability. Body mass index above 30 kg/m² can artificially raise CAP by 10 to 20 dB/m due to subcutaneous adipose tissue attenuating the ultrasound signal [6].

Functional Optimal Targets: Going Beyond "Normal"

Standard cutoffs answer one question: does this patient have diagnosable fibrosis or steatosis? Functional optimal targets answer a different one: is this liver performing at its metabolic best?

Population data support the distinction. In a study of 1,190 healthy French blood donors with no known liver disease, a BMI below 25, and normal aminotransferases, the median LSM was 4.8 kPa, with the 95th percentile at 6.2 kPa [4]. That means a stiffness reading of 6.5 kPa, while "normal" by clinical staging, exceeds the 95th percentile for metabolically healthy adults without hepatic inflammation.

For CAP, the same principle applies. The median CAP in lean, healthy adults without metabolic risk factors is approximately 200 to 210 dB/m [7]. A reading of 240 dB/m falls below the S1 steatosis cutoff but already reflects measurable hepatic fat accumulation that correlates with early insulin resistance and elevated cardiovascular risk.

Functional optimal targets that the HealthRX clinical team uses for longitudinal monitoring:

• LSM: at or below 5.0 kPa. This aligns with the median value in metabolically healthy populations and provides a buffer well below the 7.0 kPa threshold for early fibrosis.
• CAP: below 215 dB/m. This sits within the range observed in lean individuals without hepatic steatosis and below the point where measurable fat-related metabolic changes begin.

These are monitoring targets, not diagnostic cutoffs. A patient trending from 5.2 kPa down to 4.5 kPa over 12 months is demonstrating measurable hepatic improvement. That trajectory matters even though both values fall within the "normal" range.

How Fibroscan Results Connect to MASLD Treatment Decisions

MASLD affects an estimated 30% of the global adult population according to a 2023 meta-analysis published in The Lancet Gastroenterology & Hepatology (N=1,201,807 across 63 countries) [8]. The disease progresses silently through steatosis, steatohepatitis (MASH), fibrosis, and eventually cirrhosis. Fibroscan results directly inform treatment intensity at each stage.

The 2024 FDA approval of resmetirom (Rezdiffra) for MASH with moderate-to-advanced fibrosis (F2-F3) made VCTE staging even more consequential [9]. In the MAESTRO-NASH phase 3 trial (N=966), resmetirom 80 mg daily achieved MASH resolution without worsening fibrosis in 25.9% of patients at 52 weeks versus 9.7% with placebo [10]. The trial enrolled patients with biopsy-confirmed MASH and fibrosis stage F2 or F3. VCTE serves as the practical screening tool to identify candidates for biopsy confirmation and, if eligible, treatment initiation.

The AASLD 2023 guidance recommends the following care pathway: all adults with metabolic risk factors (type 2 diabetes, obesity, metabolic syndrome) should undergo fibrosis risk assessment. Patients with LSM at or above 8.0 kPa on VCTE should be referred to hepatology for further workup [2]. Dr. Mary Rinella, lead author of the AASLD guidance, has stated: "Noninvasive tests like VCTE have transformed our ability to identify patients with significant fibrosis before they develop decompensated cirrhosis" [2].

The European Association for the Study of the Liver (EASL) echoes this position. Their 2021 clinical practice guidelines on noninvasive tests state: "VCTE is the most widely validated point-of-care tool for fibrosis assessment and should be available in all settings where chronic liver disease is managed" [11].

How to Lower Your Fibroscan Score

Liver stiffness and CAP scores respond to targeted interventions. The evidence base is strong for several approaches, and measurable improvements on repeat VCTE can appear within 6 to 12 months.

Weight reduction produces the most consistent effect. In a prospective study of 293 patients with biopsy-confirmed MASH, a 10% or greater total body weight loss resulted in fibrosis regression in 45% of participants and MASH resolution in 90% [12]. This translated to meaningful LSM reductions on follow-up VCTE, with mean decreases of 2.5 to 4.0 kPa in patients achieving fibrosis improvement.

GLP-1 receptor agonists lower liver fat and may reduce fibrosis. In the LEAN trial (N=52), liraglutide 1.8 mg daily for 48 weeks resolved MASH in 39% of patients versus 9% with placebo [13]. Semaglutide data from the phase 2 trial published in the New England Journal of Medicine (N=320) showed MASH resolution in 59% of patients receiving the 0.4 mg dose versus 17% with placebo at 72 weeks [14].

Reduce alcohol intake. Even moderate alcohol consumption (7 to 14 drinks per week) can raise LSM by 1.0 to 2.0 kPa acutely and accelerate fibrosis progression in patients with existing MASLD [15].

Improve insulin sensitivity. Pioglitazone 30 to 45 mg daily reduced hepatic fibrosis in patients with MASH and type 2 diabetes in a randomized trial (N=101), with 58% achieving at least one stage of fibrosis improvement versus 26% with placebo [16].

Exercise independently of weight loss. A meta-analysis of 12 randomized controlled trials (N=555) found that aerobic exercise reduced intrahepatic lipid content by a mean of 3.31 percentage points (measured by MRI-PDFF) even when body weight remained stable [17].

When Fibroscan Scores Can Be Falsely Elevated

Certain clinical scenarios raise LSM without reflecting true fibrosis. Recognizing these confounders prevents unnecessary alarm and avoids inappropriate clinical decisions.

Postprandial state is the most common confounder. Food intake raises hepatic blood flow and portal pressure, inflating LSM by 1.0 to 2.5 kPa within 30 minutes of eating [18]. The standard recommendation is a minimum 2-hour fast before scanning, though a 4-hour fast produces more reliable results.

Active hepatic inflammation (marked by ALT above 5 times the upper limit of normal) inflates LSM independently of fibrosis. A patient with acute hepatitis and ALT of 400 U/L may show an LSM of 15.0 kPa that normalizes to 5.5 kPa once the flare resolves [1]. Hepatic congestion from right heart failure or Budd-Chiari syndrome produces similarly misleading elevations.

Other technical factors: narrow intercostal spaces, ascites, or morbid obesity (BMI >40 kg/m²) can prevent valid measurements entirely. The XL probe, designed for patients with larger body habitus, extends reliable measurement to a skin-to-liver-capsule distance of up to 75 mm versus 55 mm for the standard M probe [6].

Monitoring Frequency and Longitudinal Tracking

How often you should repeat a Fibroscan depends on your baseline result and clinical risk profile.

For patients with MASLD and LSM below 8.0 kPa, the AASLD suggests repeat assessment every 2 to 3 years unless metabolic risk factors worsen [2]. For patients in the gray zone (8.0 to 12.0 kPa), annual reassessment is appropriate, ideally combined with a secondary noninvasive marker like FIB-4 or ELF. Patients with established advanced fibrosis (LSM ≥12.0 kPa) require hepatology follow-up and may need surveillance for hepatocellular carcinoma and varices.

For patients pursuing functional optimization (starting LSM between 5.0 and 7.0 kPa), repeat VCTE every 6 to 12 months provides actionable trend data. A decrease of 1.0 kPa or more on serial measurements correlates with histological improvement in fibrosis staging [19]. Track your results alongside ALT, AST, GGT, fasting insulin, and HbA1c for a complete metabolic picture.

Patients on GLP-1 receptor agonists, pioglitazone, or resmetirom for MASH should have follow-up VCTE at 6 and 12 months to document treatment response. The MAESTRO-NASH trial used MRI-PDFF as the primary imaging endpoint, but VCTE LSM served as a secondary measure and showed concordant improvements in patients with histological fibrosis regression [10].